Palatin Börsentag ist ohne jegliche Erkenntnis auf das morgige Telefonhearing . Somit kann man auch im Vorhinein keinerlei Spekulationen für einen Kauf oder Verkauf tätigen . Die Spannung wächst - der Preis ist heiß !
Chartechnik und da es keine wirklichen schlechten und nur paar gute Nachrichten gab die den Kursverlauf der letzten Monate erklären könnten waren es Gewinmitnahmen die jetzt bei 1.10 sich stabilisiert haben.
Vyleesi?, the trade name for bremelanotide - Under development for Hypoactive Sexual Desire Disorder ("HSDD"): In June 2018, our exclusive North American Licensee for Vyleesi, AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) ("AMAG"), was notified by the U.S. Food and Drug Administration ("FDA") of acceptance for the filing of the New Drug Application ("NDA") on Vyleesi, with an FDA PDUFA (Prescription Drug User Fee Act) goal date for completion of the FDA review of the NDA of March 23, 2019. FDA's acceptance of the NDA triggered a $20 million milestone payment to Palatin, less expenses paid by AMAG. Palatin is entitled to receive up to $60 million upon regulatory approval by the FDA. If approved, Vyleesi would become the first and only on-demand pharmacologic option indicated for the treatment of HSDD in premenopausal women in the U.S. Entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. ("Fosun"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd in September 2017 for exclusive rights to develop and commercialize Vyleesi in the territories of mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Received $4,500,000 in October 2017, consisting of an upfront payment of $5,000,000 less $500,000, which was withheld in accordance with tax withholding requirements in China. Entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. ("Kwangdong") in November 2017 for exclusive rights to develop and commercialize Vyleesi in the Republic of Korea. Received $417,500 in December 2017, consisting of an upfront payment of $500,000 less $82,500 which was withheld in accordance with tax withholding requirements in the Republic of Korea. PL-8177 / PL-8331
Melanocortin Receptor 1 (MC1r) Agonists under development for the treatment of inflammatory and autoimmune diseases such as dry eye, uveitis, diabetic retinopathy and inflammatory bowel diseases: Completed subcutaneous dosing of human subjects with PL-8177 in a Phase 1 single and multiple ascending dose clinical safety study, with data expected in the fourth quarter of calendar 2018. May 2018 ? Presented positive preclinical data on PL-8331 at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting. April 2018 ? Presented preclinical oral formulation data on PL-8177, an investigational MC1r agonist for Inflammatory Bowel Diseases at the 2018 Keystone Symposia on "The Resolution of Inflammation in Health and Disease."
: Decreased debt from $14.8 million at June 30, 2017
Fourth Quarter and Fiscal 2018 Financial Results Palatin reported net income of $11.8 million, or $0.06 per basic and diluted share, for the fourth quarter ended June 30, 2018, compared to net income of $13.3 million, or $0.07 per basic and diluted share, for the same period in 2017.
The difference between the three months ended June 30, 2018 and 2017 was primarily attributable to the recognition of contract revenue pursuant to our license agreement with AMAG of $20.6 million for the quarter ended June 30, 2018 compared to $33.9 million in 2017.
For the fiscal year ended June 30, 2018, Palatin reported net income of $24.7 million, or $0.12 per basic and diluted share compared to a net loss of $(13.3) million, or $(0.07) per basic and diluted share for the year ended June 30, 2017.
The difference in net income for the year ended June 30, 2018, and the net loss for the year ended June 30, 2017, was primarily attributable to the recognition of $67.1 million in license and contract revenue for the year ended June 30, 2018 compared to $44.7 million for the year ended June 30, 2017, and secondarily to a $14.1 million decrease in operating expenses to $41.2 million for the year ended June 30, 2018 compared to $55.3 million for the year ended June 30, 2017.
Wenn diese good News 20, 30 % Plus bringen würden, dann könnte ich es ja verstehen. Aber jetzt...lächerlich. Da warte ich lieber noch ein wenig, bis die richtig guten News kommen, die dann auch richtige Kurssprünge bringen.
ab 15.30 Uhr wird uns zeigen , ob der Quartalsbericht eine positive Substanz enthält . Die verringerten Einnahmen , da es sich um eine Forschungs- und Entwicklungsfirma handelt, dürften eigentlich kein Grund sein. Nach wie vor geht es um die 3. Phase und die Zulassung Anfang 1919.
hier 500 Euronen verschossen . Musste schnell , also vor einer Stunde 60 K Steinhoff kaufen , um aus den Miesen raus zu kommen. Bevor aber hier verkaufe , muss ich den heutigen Handel noch mal abwarten.